drugset / Trial / NCT07560020

A Trial to Compare Treatment With Surlorian (ARM210, S48168) to Placebo in Effects on Muscle Strength and Safety in Adults With Autosomal Dominant RYR1-related Myopathy

NCT07560020 ↗

Phase 2 Recruiting 28 enrolled RyCarma Therapeutics, Inc.
RandomizedCrossoverDouble-blindTreatment

Summary

This study is testing a medicine called surlorian in adults who have a genetic muscle condition known as autosomal dominant RYR1-related myopathy (RYR1-RM). The goal is to find out whether surlorian improves muscle weakness, and whether it is safe and well tolerated.

Timeline

Start
2026-07-01
Primary completion
2027-08-27
Completion
2028-08-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Surlorian Small molecule 300 mg —

Indications